Novo Nordisk will invest $2 billion starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Hillerød, Denmark to support its future portfolio in serious chronic diseases.

The facility will create additional production capacity and increase its ability to meet future market demands for its late-phase product portfolio. Construction is underway and the facility is expected to start producing API by early 2029. The project is expected to create 340 new jobs when construction is completed.

The new 65,000 square-meter facility will be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment.

“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, executive vice president of Product Supply, Quality & IT.